

Policy Number	SUR703.010
Policy Effective Date	01/01/2026

Lung and Lobar Lung Transplant

Table of Contents
Coverage
Policy Guidelines
Description
Rationale
Coding
References
Policy History

Related Policies (if applicable)
SUR703.001: Organ and Tissue Transplantation (General Donor and Recipient Information)
SUR703.006: Heart/Lung Transplant

Disclaimer

Carefully check state regulations and/or the member contract.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. **If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.**

Legislative Mandates

EXCEPTION: For Texas ONLY: For policies (IFM, Student, Small Group, Mid-Market, Large Group, fully-insured Municipalities/Counties/Schools, State Employee Plans, PPO, HMO, POS) delivered, issued for delivery, or renewed on or after January 1, 2024, TIC Chapter 1380 (§§ 1380.001 – 1380.003 [SB 1040 Human Organ Transplant]) prohibits coverage of a human organ transplant or post-transplant care if the transplant operation is performed in China or another country known to have participated in forced organ harvesting; or the human organ to be transplanted was procured by a sale or donation originating in China or another country known to have participated in forced organ harvesting. The commissioner of state health services may designate countries who are known to have participated in forced organ harvesting. Forced organ harvesting is defined as the removal of one or more organs from a living person by means of coercion, abduction, deception, fraud, or abuse of power or a position of vulnerability.

Coverage

Lung transplantation **may be considered medically necessary** for carefully selected individuals with end-stage pulmonary disease (ESPD), including but not limited to, one of the conditions listed below.

A lobar lung transplant from a living or deceased donor **may be considered medically necessary** for carefully selected individuals with ESPD, including but not limited to one of the conditions listed below.

Examples of conditions associated with end-stage pulmonary disease:

- Alpha-1 antitrypsin deficiency,
- Bronchiectasis,
- Bronchiolitis obliterans,
- Bronchopulmonary dysplasia,
- Pulmonary hypertension,
- Chronic obstructive pulmonary disease (COPD),
- Cystic fibrosis (CF) (both lungs to be transplanted),
- Eisenmenger's syndrome,
- Emphysema,
- Eosinophilic granuloma,
- Idiopathic or interstitial pulmonary fibrosis,
- Lymphangiomyomatosis,
- Sarcoidosis,
- Scleroderma.

Lung or lobar lung transplantation, after a failed lung or lobar lung transplant, **may be considered medically necessary** in individuals who meet the criteria for lung transplantation.

Lung or lobar lung transplantation **is considered experimental, investigational and/or unproven** in all other clinical situations.

Policy Guidelines

Contraindications

The factors below are potential contraindications subject to the judgment of the transplant center:

- Known current malignancy, including metastatic cancer;
- Recent malignancy with high risk of recurrence;
- Untreated systemic infection making immunosuppression unsafe, including chronic infection;
- Other irreversible end-stage diseases not attributed to lung disease;
- History of cancer with a moderate risk of recurrence;
- Systemic disease that could be exacerbated by immunosuppression;
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy.

Policy specific:

- Coronary artery disease not amenable to percutaneous intervention or bypass grafting, or associated with significant impairment of left ventricular function^a; or
 - Colonization with highly resistant or highly virulent bacteria, fungi, or mycobacteria.
- ^a Some individuals may be candidates for combined heart and lung transplantation (see Medical Policy SUR703.006 Heart/Lung Transplant).

Individuals must meet United Network for Organ Sharing guidelines for a Lung Allocation Score greater than zero.

Lung-Specific Guidelines

Bilateral lung transplantation is typically required when chronic lung infection and disease is present (i.e., associated with cystic fibrosis and bronchiectasis). Some, but not all, cases of pulmonary hypertension will require bilateral lung transplantation.

Bronchiolitis obliterans is associated with chronic lung transplant rejection and thus may be the etiology of a request for lung retransplantation.

Description

A lung transplant consists of replacing all or part of diseased lungs with healthy lung(s) or lobes. Transplantation is an option for patients with end-stage lung/pulmonary disease (ESPD).

Background

Solid organ transplantation offers a treatment option for patients with different types of end-stage organ failure that can be lifesaving or provide significant improvements to a patient's quality of life. (1) Many advances have been made in the last several decades to reduce perioperative complications. Available data supports improvement in long-term survival as well as improved quality of life particularly for liver, kidney, pancreas, heart, and lung transplants. Allograft rejection remains a key early and late complication risk for any organ transplantation. Transplant recipients require life-long immunosuppression to prevent rejection. Patients are prioritized for transplant by mortality risk and severity of illness criteria developed by the Organ Procurement and Transplantation Network (OPTN) and United Network of Organ Sharing.

Lung Transplant

In 2024, 48,136 transplants were performed in the United States procured from more than 41,000 deceased donors and 6,900 living donors. (2) Lung transplants were the fourth most common procedure with 3,339 transplants performed from both deceased and living donors in 2024.

End-stage lung disease may derive from different etiologies. The most common indications for lung transplantation are chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, cystic fibrosis (CF), alpha-1 antitrypsin deficiency, and idiopathic pulmonary arterial hypertension (PAH). Before consideration for transplant, patients should be receiving maximal

medical therapy, including oxygen supplementation, or surgical options, such as lung-volume reduction surgery for COPD. Lung or lobar lung transplantation is an option for patients with ESPD despite these measures.

A lung transplant refers to single-lung or double-lung replacement. In a single-lung transplant, only 1 lung from a deceased donor is provided to the recipient. In a double-lung transplant, both the recipient's lungs are removed and replaced by the donor's lungs. In a lobar transplant, a lobe of the donor's lung is excised, sized appropriately for the recipient's thoracic dimensions, and transplanted. Donors for lobar transplant have primarily been living-related donors, with 1 lobe obtained from each of 2 donors (generally friends or family members) in cases for which bilateral transplantation is required. There are also cases of cadaver lobe transplants.

Potential recipients who are 12 years of age and older are ranked according to the Lung Allocation Score (LAS). (3) A score may range between 0 and 100 and incorporates predicted survival after transplantation and predicted survival on the waiting list; the LAS takes into consideration the patient's disease and clinical parameters. The waiting list incorporates the LAS, geography, and blood type classifications. Children younger than 12 years old receive priority for lung allocation. Under this system, children younger than 12 years old with respiratory lung failure and/or pulmonary hypertension who meet criteria are considered "priority 1", and all other candidates in the age group are considered "priority 2". A lung review board has the authority to adjust scores on appeal for adults and children.

Potential Contraindications to Transplantation

Malignancy

Malignancies are common after lung transplantation, with 21% and 40% of patients reporting 1 or more malignancies at 5 and 10 years posttransplantation, respectively. (4) Skin cancer occurred most frequently, and lymphoproliferative disorders were the malignancies most associated with morbidity posttransplantation.

Human Immunodeficiency Virus Infection

Current OPTN policy permits human immunodeficiency virus (HIV)-positive transplant candidates. The 2020 U.S. Public Health Service guideline also allows for transplantations in HIV-positive recipients with proper screenings and effective regimens for HIV infections; it recommended that all transplant candidates receive HIV, hepatitis b virus (HBV), and hepatitis C virus (HCV) testing during hospital admission for transplant surgery. (5) In 2022, the U.S. Public Health Service published updated guidance for testing transplant candidates aged less than 12 years of age. (6) They recommended that children less than 12 years of age who have received postnatal infectious disease testing are exempt from repeat pretransplant HIV, HBV, and HCV testing during hospital admission for transplant surgery.

The British HIV Association and the British Transplantation Society (2017) updated their guidelines on kidney transplantation in patients with HIV disease. (7) These criteria for adding a patient to the waitlist may be extrapolated to other organs:

- Adherent with treatment, particularly antiretroviral therapy,

- Cluster of Differentiation 4 count greater than 100 cells/mL (ideally >200 cells/mL) for at least 3 months,
- Undetectable HIV viremia (<50 HIV-1 RNA copies/mL) for at least 6 months,
- No opportunistic infections for at least 6 months,
- No history of progressive multifocal leukoencephalopathy, chronic intestinal cryptosporidiosis, or lymphoma.

Other Infections

Infection with *Burkholderia cenocepacia* is associated with increased mortality in some transplant centers, a factor that may be considered when evaluating the overall risk of transplant survival. (8) Two articles have evaluated the impact of infection with various species of *Burkholderia* on outcomes for lung transplantation for cystic fibrosis. In a study by Murray et al. (2008), multivariate Cox survival models were applied to 1026 lung transplant candidates and 528 transplant recipients. (9) Of the transplant recipients, 88 were infected with *Burkholderia*. Among transplant recipients infected with *B. cenocepacia*, only those infected with nonepidemic strains (n=11) had significantly greater posttransplant mortality than uninfected patients (hazard ratio [HR], 2.52; 95% CI, 1.04 to 6.12; p=.04). Transplant recipients infected with *Burkholderia gladioli* (n=14) also had significantly greater posttransplant mortality than uninfected patients (HR, 2.23; 95% CI, 1.05 to 4.74; p=.04). When adjustments for specific species or strains were included, the LAS of *Burkholderia multivorans*-infected transplant candidates were comparable with uninfected candidate scores, and scores for patients infected with nonepidemic *B. cenocepacia* or *B. gladioli* were lower. In a smaller study of 22 patients colonized with *Burkholderia cepacia* complex who underwent lung transplantation in 2 French centers, Boussaud et al. (2008) reported that the risk of death by univariate analysis was significantly higher for the 8 patients infected with *B. cenocepacia* than for the other 14 colonized patients (11 of whom had *B. multivorans*). (10)

An analysis of international registry data by Yusen et al. (2016) found that non-cytomegalovirus (CMV) infection is a major cause of mortality within 30 days of a lung transplant in adults. (11) A total of 655 (19%) of 3424 deaths after transplants between 1990 and 2015 were due to non-CMV infection. Only 3 (0.1%) of the deaths were due to CMV infection.

Regulatory Status

Solid organ transplants are a surgical procedure and, as such, are not subject to regulation by the U.S. Food and Drug Administration (FDA).

The FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation Title 21, parts 1270 and 1271. Solid organs used for transplantation are subject to these regulations.

Rationale

Medical policies assess clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: relevance, quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Lung Transplantation for End-Stage Pulmonary Disease

Clinical Context and Therapy Purpose

The purpose of lung transplantation in individuals who have end-stage pulmonary disease is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this medical policy.

Populations

The relevant population of interest is individuals with end-stage pulmonary disease.

Before consideration for transplant, patients should be receiving maximal medical therapy, including oxygen supplementation, or surgical options, such as lung volume reduction surgery for chronic obstructive pulmonary disease (COPD).

Interventions

The therapy being considered is a lung transplant.

Comparators

The following practice is currently being used to make decisions about reducing the risk of end-stage pulmonary disease: medical management, such as maximal medical therapy, including oxygen supplementation, or surgical options, such as lung volume reduction surgery for COPD.

Outcomes

The general outcomes of interest are overall survival (OS), change in disease status, treatment-related mortality, and treatment-related morbidity (e.g., immunosuppression, graft failure, surgical complications, infections, cardiovascular complications, malignancies). Short-term follow-up ranges from immediate postsurgery to 30 days posttransplantation; lifelong follow-up (out to at 10 years or more given current survival data) is necessary to due immunosuppression drugs and risk of graft failure.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Registry Studies

Paraskeva et al. (2018) analyzed survival rates of adolescent lung transplant recipients using data from the International Society for Heart and Lung Transplantation (ISHLT) Registry. (12) Patients between 10 and 24 years old represented 9% of the registry data (n=2319) and they were compared with both old and young cohorts. Overall survival in the adolescent cohort was 65% at 3 years, which was similar to that observed in adults between 50 and 65 years of age, but significantly lower than 3-year survival rate among the pediatric subgroup (73%; $p=0.006$) or adults 25 to 34 years old (75%; $p<0.001$) and 35 to 49 years old (71%; $p<0.001$). Within the adolescent group, patients between 15 and 19 years of age had the poorest survival rates at 3 years (59%) compared with 10- to 14-year-old patients (73; $p<0.001$) and 20- to 24-year old patients (66%; $p<0.001$). The registry study was biased toward inclusion of North American data and potential data entry errors or missing data. There were no data reported on the cause of mortality, differences in regimens, or rates of graft dysfunction between the groups.

One of the ISHLT registries contained data from 49,453 adult recipients who received lung transplantation (including lung retransplantation) through June 30, 2015, at 134 transplant centers. (11) A total of 55,795 lung transplants were performed, of which 53,522 (95.9%) were primary transplants and 2273 (4.1%) were retransplants. The overall median survival of patients who underwent lung transplantation was 5.8 years. Estimated unadjusted survival rates were 89% at 3 months, 80% at 1 year, 65% at 5 years, and 32% at 10 years. Patients who survived a year after primary transplantation had a median survival of 8 years. In the first 30 days after transplantation, the major reported causes of mortality were graft failure (24.5%) and non-cytomegalovirus (CMV) infections (19.1%) while non-CMV infections became the major cause of death for the remainder of the first year. Beyond the first year, the most commonly reported causes of mortality were obstructive bronchiolitis/bronchiolitis obliterans syndrome, graft failure, and non-CMV infections. Beyond 10 years posttransplant, the major causes of mortality

were obstructive bronchiolitis/bronchiolitis obliterans syndrome (21.5%), non-CMV infection (16.5%), and nonlymphoma malignancy (13.7%).

Through 2014, another ISHLT registry contained 2229 pediatric lung transplants. (13) Most transplants (73%) were done in children between the ages of 11 and 17 years. Median survival in children who underwent lung transplantation was 5.4 years, similar to survival in adults (mean survival, 5.7 years). However, median survival in children was lower (2.2 years) than in adults (5.6 years) for single-lung transplants.

Thabut et al. (2010) reported on a comparison between patients undergoing single- and double-lung transplantation for idiopathic pulmonary fibrosis. (14) A retrospective review was conducted of 3327 patients with data in the United Network for Organ Sharing (UNOS) registry. More patients underwent single-lung transplant (64.5%) compared with double-lung transplant (35.5%). Median survival time was greater for the double-lung group at 5.2 years (95% confidence interval [CI], 4.3 to 6.7 years) than 3.8 years (95% CI, 3.6 to 4.1 years; $p < 0.001$). After adjusting for baseline differences, however, survival times did not differ statistically. The authors concluded that OS did not differ between the groups: single-lung transplants offered improved short-term survival but a reduced long-term benefit, whereas double-lung transplant increased short-term harm but was associated with a long-term survival benefit. Black et al. (2014) reported on Lung Allocation Score (LAS) and single versus double-lung transplant in 8778 patients (8050 had a LAS < 75 vs 728 had a LAS ≥ 75). (15) A significant decrease in survival was seen in single-lung transplant patients with a high LAS compared with double-lung transplant patients with a high LAS ($p < 0.001$). Yu et al. (2019) compared double-lung with single-lung transplantations for outcomes of survival, pulmonary function, surgical indicators, and complications in a meta-analysis of 30 studies ($n = 1980$ recipients of single-lung transplants and $n = 2112$ recipients of double-lung transplants). (16) Overall survival, in-hospital mortality, and postoperative complications besides bronchiolitis obliterans syndrome were similar between the 2 groups. Recipients of double-lung transplants had lower rates of bronchiolitis obliterans syndrome, better postoperative lung function, and improved long-term survival, while recipients of single-lung transplants spent less time in surgery, the postoperative intensive care unit, and the postoperative hospital stay.

Yusen et al. (2010) reviewed the effect of the LAS on lung transplantation by comparing statistics for the period before and after its implementation in 2005. (17) Other independent changes in clinical practice, which may affect outcomes over the same period of time, include variation in immunosuppressive regimens, an increased supply of donor lungs, changes in diagnostic mix, and increased consideration of older recipients. Deaths on the waiting list declined following implementation of the LAS system, from approximately 500 per 5000 patients to 300 per 5000 patients. However, it is expected that implementation of LAS affected patient characteristics of transplant applicants. One-year survival posttransplantation did not improve after implementation of the LAS system: patient survival data before and after were approximately 83%. Long-term survival data are not yet available. Shafii et al. (2014) reported on a retrospective evaluation of the LAS and mortality in 537 adults listed for lung transplantation and 426 who underwent primary lung transplantation between 2005 and 2010.

(18) Patients on the wait list who had a higher LAS had a higher mortality rate ($p<0.001$). In the highest quartile of LAS (range, 47-95), within 1 year of listing, there was a 75% mortality rate. Higher LAS was also associated with early posttransplant survival ($p=0.05$) but not late posttransplant survival ($p=0.4$). When other predictive factors of early mortality were taken into account, pretransplant LAS was not independently related to posttransplant mortality ($p=0.12$).

Section Summary: Lung Transplant for End-Stage Pulmonary Disease

International registry data on a large number of patients receiving lung transplantation (>50,000) found relatively high patient survival rates (89% at 3 months, 80% at 1 year, 65% at 5 years, 32% at 10 years). In patients who survived at least 1-year, median survival was 8 years. After adjusting for potential confounding factors, survival did not differ significantly after single- or double-lung transplant. A subgroup analysis of an international registry study found decreased survival for adolescent patients, especially between 15 and 19 years of age, who received lung transplantation, but the study was limited by inclusion bias and lack of data on mortality, differences in treatment regimens, and rates of graft dysfunction.

Lobar Lung Transplantation for End-Stage Pulmonary Disease

Clinical Context and Test Purpose

The purpose of lobar lung transplantation in individuals who have end-stage pulmonary disease is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with end-stage pulmonary disease.

Before consideration for transplant, individuals should be receiving maximal medical therapy, including oxygen supplementation, or surgical options, such as lung volume reduction surgery for COPD.

Interventions

The therapy being considered is a lobar lung transplant.

Date (2011) published that, as of 2011, approximately 400 living-donor lobar lung transplants had been performed worldwide. (19) Procedures in the United States decreased after 2005 due to changes in the lung allocation system. Date also reported that size matching between donor and recipient is important and that, to some extent, size mismatching (oversized or undersized grafts) can be overcome by adjusting surgical technique.

Comparators

The following practice is currently being used to make decisions about end-stage pulmonary disease: medical management, such as maximal medical therapy, including oxygen supplementation, or surgical options, such as lung volume reduction surgery for COPD.

Outcomes

The general outcomes of interest are OS, change in disease status, treatment-related mortality, and treatment-related morbidity (e.g., immunosuppression, graft failure, surgical complications, infections, cardiovascular complications, malignancies). Short-term follow-up ranges from immediate postsurgery to 30 days post transplantation; lifelong follow-up (out to at 10 years or more given current survival data) is necessary to due immunosuppression drugs and risk of graft failure.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Systematic Reviews

Eberlein et al. (2017) reported on a systematic review of studies on lobar lung transplantation from deceased donors. (20) Reviewers identified 9 studies comparing outcomes after lobar lung or lung transplant, all of which were single-center retrospective cohort studies. Seven studies were conducted in Europe, 1 in Australia and 1 in North America. One-year survival reported in individual studies ranged from 50% to 100% after lobar lung transplant and from 72% to 88% after conventional lung transplant. In a pooled analysis of data from 8 studies, lobar lung transplant recipients (n=284) had a significantly higher risk of 1-year mortality than lung transplant recipients (n=2777) (relative risk [RR], 1.85; 95% CI, 1.52 to 2.25; $p<0.001$; $I^2=0\%$).

Retrospective Studies

Several studies have reported on lobar lung transplantation from living donors. For example, Barr et al. (2005) reported on living-donor lobar lung transplants in the United States. (21) Ninety patients were adults and 43 were children. The primary indication for transplantation (86%) was cystic fibrosis. At the time of transplantation, 67% of patients were hospitalized and 20% were ventilator dependent. Overall recipient survival rates at 1, 3, and 5 years were 70%, 54%, and 45%, respectively. There was no statistically significant difference in actuarial survival between adults and children who underwent transplantation. Moreover, survival rates were similar to the general population of lung transplant recipients. The authors also reported that rates of postoperative pulmonary function in patients surviving more than 3 months posttransplant were comparable with rates in cadaveric lung transplant recipients.

Date et al. (2015) reported on a retrospective study comparing 42 living-donor lobar lung transplants with 37 cadaveric lung transplants. (22) Survival rates at 1 and 3 years did not differ significantly between groups (89.7% and 86.1% vs 88.3% and 83.1%, respectively, $p=0.55$), despite living-donor lobar lung transplant patients having poorer health status preoperatively. For a program in Japan, Date et al. (2012) reported on 14 critically ill patients (10 children, 4 adults) who had undergone single living-donor lobar lung transplants. (23) Patients were followed for a mean 45 months. The 3-year survival rate was 70% and the 5-year survival was 56%. Severe graft dysfunction occurred in 4 patients. Mean forced vital capacity (FVC) was lower in patients experiencing severe graft dysfunction (54.5%) than in the other patients (66.5%). The authors postulated that this suggests size mismatching in the patients with severe graft dysfunction.

Slama et al. (2014) reported on a comparison of outcomes in 138 cadaveric lobar lung transplants (for size discrepancies) with 778 patients who received cadaveric whole-lung transplants, 239 of whom had downsizing by wedge resection of the right middle lobe and/or the left lingula. (24) Survival rates in the lobar lung transplant group at 1 and 5 years was 65.1% and 54.9% vs 84.8% and 65.1% in the whole-lung and downsized by wedge resection group ($p<0.001$). The lobar lung transplantation group experienced significantly inferior early postoperative outcomes, but in patients who were successfully discharged, survival rates were similar to standard lung transplantation ($p=0.168$).

Section Summary: Lung Lobar Transplant for End-Stage Pulmonary Disease

There is less data on lung lobar transplants than on whole-lung transplants. The available data reported in case series have suggested reasonably similar survival outcomes, and lung lobar transplants may be the only option for patients unable to wait for a whole lung. A 2017 systematic review found 1-year survival rates ranging from 50% to 100%.

Lung or Lobar Retransplantation When Meeting Criteria for a Lung Transplant

Clinical Context and Therapy Purpose

The purpose of lung retransplantation in individuals who have had a prior lung or lobar transplant and who meet criteria for a lung transplant is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with a prior lung or lobar transplant who meet criteria for a lung transplant.

Interventions

The therapy being considered is lung or lobar retransplantation.

Comparators

The following practice is currently being used to make decisions about treating those whose lung or lobar transplant has failed and would still be considered as meeting eligibility criteria for an initial transplant: medical management, such as maximal medical therapy, including oxygen supplementation, or surgical options, such as lung volume reduction surgery for COPD.

Outcomes

The general outcomes of interest are OS, change in disease status, treatment-related mortality, and treatment-related morbidity (e.g., immunosuppression, graft failure, surgical complications, infections, cardiovascular complications, malignancies). Short-term follow-up ranges from immediate postsurgery to 30 days posttransplantation; lifelong follow-up.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Case Series

Registry data and case series have demonstrated favorable outcomes with lung retransplantation in certain populations, such as in patients who meet criteria for initial lung transplantation. (4, 25, 26)

Biswas Roy et al. (2018) published a single-center retrospective study comparing survival outcomes in 29 patients who received retransplantation for chronic lung allograft dysfunction with 390 patients receiving a primary lung transplant at the same center. (27) Patients receiving retransplantation had significantly higher use of extracorporeal membrane oxygenation support for severe primary graft dysfunction ($p=0.019$) and underwent cardiopulmonary bypass and re-exploration for bleeding ($p=0.019$) more frequently than patients receiving primary transplantation ($p=0.029$). At 1-year follow-up, 89.7% of primary transplant patients were living, as were 89.2% of retransplantation patients. At 5-year follow-up, a greater percentage of the retransplantation group had survived, compared with the primary transplantation group (64.3% vs 58.2%), although the difference was not statistically significant. While high LAS and extended hospital length of stay were both identified as independent mortality risk factors, retransplantation was not (hazard ratio [HR], 1.58; 95% CI, 0.31 to 8.08; $p=0.58$). Study limitations included its single-center, retrospective design, the potential selection bias for younger patients, and the small size of the retransplantation group. Further, follow-up data at 3 and 5 years were incomplete for some patients and patients who were refused retransplantation were not considered in the analyses. However, for appropriately selected patients, retransplantation after chronic lung allograft dysfunction resulted in 1- and 5-year survival rates comparable to those seen after primary lung transplantation.

Registry Studies

The Organ Procurement and Transplantation Network (OPTN) reported data on lung transplants performed between 2008 and 2015. (28) Patient survival rates after repeat transplants were lower than primary transplants, but a substantial number of patients survived. For example, 1-year patient survival was 87.2% (95% CI, 86.4% to 87.9%) after a primary lung transplant and 76% (95% CI, 71.0% to 80.2%) after a repeat transplant. Five-year patient survival rates were 53.4% (95% CI, 52.2% to 54.7%) after a primary lung transplant and 32.9% (95% CI, 27.7% to 38.2%) after repeat transplant.

The ISHLT Registry contained data on 2273 retransplantation patients performed through June 2015 (4.4% of lung transplantations). (11) The major causes of death in the first 30 days after retransplantation were graft failure and non-CMV infection, followed by multiorgan failure, cardiovascular causes, and technical factors related to the transplant procedure. Beyond the first year, the most commonly reported causes of mortality were obstructive bronchiolitis/bronchiolitis obliterans, graft failure, and non-CMV infections.

Section Summary: Lung or Lobar Retransplant When Meeting Criteria for a Lung Transplant

Data from registries and case series have found favorable outcomes with lung retransplantation in patients who meet criteria for initial lung transplantation. Given the exceedingly poor survival without retransplantation of patients who have exhausted other treatments, evidence of a moderate level of posttransplant survival is sufficient to suggest treatment efficacy in this patient population.

Summary of Evidence

For individuals who have end-stage pulmonary disease who receive a lung transplant, the evidence includes case series and registry studies. Relevant outcomes are overall survival (OS), change in disease status, and treatment-related mortality and morbidity. International registry data on a large number of patients receiving lung transplantation (>50,000), found relatively high patient survival rates, especially among those who survived the first year posttransplant. After adjusting for potential confounding factors, survival did not differ significantly after single- or double-lung transplant. Lung transplantation may be the only option for some patients with end-stage lung disease. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have end-stage pulmonary disease who receive a lobar lung transplant, the evidence includes case series and systematic reviews. Relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. There are less data on lung lobar transplants than on whole-lung transplants, but several case series have reported reasonably similar survival outcomes between the procedures, and lung lobar transplants may be the only option for patients unable to wait for a whole-lung transplant. A 2017 systematic review found 1-year survival rates in available published studies ranging from 50% to 100%. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have a prior lung or lobar transplant who meet criteria for a lung transplant who receive a lung or lobar lung retransplant, the evidence includes case series and registry studies. Relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Data from registries and case series have found favorable outcomes with lung retransplantation in patients who meet criteria for initial lung transplantation. Given the exceedingly poor survival prognosis without retransplantation of patients who have exhausted other treatments, the evidence of a moderate level of posttransplant survival may be considered sufficient in this patient population. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

American Thoracic Society (ATS) et al.

Evidence-based recommendations from the ATS and 3 international cardiac societies were published in 2011 for the diagnosis and management of patients with idiopathic fibrosis. (29) For appropriately selected patients with idiopathic pulmonary fibrosis, the international guideline panel recommended lung transplantation (strong recommendation, low-quality evidence). An update to this document was published in 2015 in which the committee did not make a recommendation regarding single versus bilateral lung transplantation in patients with idiopathic fibrosis. (30) The committee stated that "it is unclear whether single or bilateral lung transplantation is preferential for long-term outcomes."

In 2022, the American Thoracic Society along with the 3 other international cardiac societies published updated guidance on diagnosis and management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. (31) In terms of treatment considerations, the committee stated that "patients at increased risk of mortality should be referred for lung transplantation at diagnosis."

In 2014, the ATS published guidelines on the management of bronchiolitis obliterans syndrome in lung transplant recipients in conjunction with the International Society for Heart and Lung Transplantation (ISHLT) and the European Respiratory Society. (32) The guideline recommends referral to a transplant surgeon to be evaluated for retransplantation for end-stage bronchial obliterans syndrome that is refractory to other therapies.

In 2025, the ATS published guidelines on interventional strategies for children with progressive pulmonary hypertension. (33) Recommendations made regarding lung transplantation are below:

- "We suggest lung transplantation in children with progressive PH [pulmonary hypertension] and RV [right ventricular] failure despite optimal therapy (conditional recommendation, very low certainty of evidence)."
- "We suggest lung transplantation in children with progressive PH and RV failure despite optimal therapy who are on ECMO [extracorporeal membrane oxygenation] support without reversible cause (conditional recommendation, very low certainty of evidence)."

International Society for Heart and Lung Transplantation

Initial Transplant

In 2021, the ISHLT published consensus-based guidelines on selection of lung transplant candidates. (34) The guidelines state that:

"Lung transplantation should be considered for adults with chronic, end-stage lung disease who meet all the following general criteria:

1. High (>50%) risk of death from lung disease within 2 years if lung transplantation is not performed.
2. High (>80%) likelihood of 5-year post-transplant survival from a general medical perspective provided that there is adequate graft function."

The guideline also notes risk factors to be considered in the evaluation of transplant candidates, along with pediatric and disease-specific considerations.

Retransplant

The 2021 guideline update briefly addressed lung retransplantation, with the consensus statement noting that "The outcomes after re-transplants are inferior compared to first lung transplants, particularly if the re- transplant is done within the first year after the original transplant or for patients with restrictive allograft syndrome (RAS) [...] In the pre-transplant evaluation of such patients, particular emphasis should be focused on understanding the possible reasons for the graft failure, such as alloimmunization, poor adherence, gastroesophageal reflux, or repeated infections." (34)

Medicare National Coverage

Lung transplantation is covered under Medicare when performed in a facility approved by Medicare as meeting institutional coverage criteria. (35) The Centers for Medicare & Medicaid Services have stated that, under certain limited cases, exceptions to the facility-related criteria may be warranted if there is justification and the facility ensures safety and efficacy objectives.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this policy are listed in Table 1.

Table 1. Summary of Key Trials

NCT Number	Trial Name	Planned Enrollment	Completion Date
NCT00177918	Prospective Evaluations of Infectious Complication in Lung Transplant Recipients	600	Dec 2025

NCT: national clinical trial.

Coding

Procedure codes on Medical Policy documents are included **only** as a general reference tool for each policy. **They may not be all-inclusive.**

The presence or absence of procedure, service, supply, or device codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. **Only the written coverage position in a Medical Policy should be used for such determinations.**

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member's benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT Codes	32850, 32851, 32852, 32853, 32854, 32855, 32856
HCPCS Codes	S2060, S2061, S2152

*Current Procedural Terminology (CPT®) ©2024 American Medical Association: Chicago, IL.

References

1. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21st century. *Ann Transl Med.* Oct 2018; 6(20):409. PMID 30498736
2. Transplant trends. United Network for Organ Sharing website. Updated July 28, 2025. Available at <<https://unos.org>> (accessed July 28, 2025).
3. Organ Procurement and Transplantation Network (OPTN). Policy 10: Allocation of Lungs (updated December 11, 2025). Available at <<https://optn.transplant.hrsa.gov>> (accessed December 19, 2025).
4. Yusen RD, Christie JD, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Report--2013; focus theme: age. *J Heart Lung Transplant.* Oct 2013; 32(10):965-978. PMID 24054805
5. Jones JM, Kracalik I, Levi ME, et al. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. *MMWR Recomm Rep.* Jun 26 2020; 69(4):1-16. PMID 32584804
6. Free RJ, Levi ME, Bowman JS, et al. Updated U.S. Public Health Service Guideline for testing of transplant candidates aged 12 years for infection with HIV, hepatitis B virus, and hepatitis C virus - United States, 2022. *Am J Transplant.* Sep 2022; 22(9):2269-2272. PMID 36039545
7. Working Party of the British Transplantation Society. Kidney and Pancreas Transplantation in Patients with HIV. Second Edition (Revised). British Transplantation Society Guidelines. Macclesfield, UK: British Transplantation Society; 2017.
8. Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with *Burkholderia cepacia* complex. *Am J Transplant.* May 2008; 8(5):1025-1030. PMID 18318775
9. Murray S, Charbeneau J, Marshall BC, et al. Impact of *Burkholderia* infection on lung transplantation in cystic fibrosis. *Am J Respir Crit Care Med.* Aug 15 2008; 178(4):363-371. PMID 18535253
10. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with *Burkholderia cepacia* complex: results from two French centres. *Thorax.* Aug 2008; 63(8):732-737. PMID 18408050
11. Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016;

Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. Oct 2016; 35(10):1170-1184. PMID 27772669

12. Paraskeva MA, Edwards LB, Levvey B, et al. Outcomes of adolescent recipients after lung transplantation: An analysis of the International Society for Heart and Lung Transplantation Registry. *J Heart Lung Transplant*. Feb 17 2018; 37(3):323-331. PMID 28320631
13. Goldfarb SB, Levvey BJ, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart-Lung Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. Oct 2016; 35(10):1196-1205. PMID 27772671
14. Thabut G, Christie JD, Kremers WK, et al. Survival differences following lung transplantation among US transplant centers. *JAMA*. Jul 7 2010; 304(1):53-60. PMID 20606149
15. Black MC, Trivedi J, Schumer EM, et al. Double lung transplants have significantly improved survival compared with single lung transplants in high lung allocation score patients. *Ann Thorac Surg*. Nov 2014; 98(5):1737-1741. PMID 25110334
16. Yu H, Bian T, Yu Z, et al. Bilateral lung transplantation provides better long-term survival and pulmonary function than single lung transplantation: a systematic review and meta-analysis. *Transplantation*. Dec 2019; 103(12):2634-2644. PMID 31283687
17. Yusen RD, Shearon TH, Qian Y, et al. Lung transplantation in the United States, 1999-2008. *Am J Transplant*. Apr 2010; 10(4 Pt 2):1047-1068. PMID 20420652
18. Shafii AE, Mason DP, Brown CR, et al. Too high for transplantation? Single-center analysis of the lung allocation score. *Ann Thorac Surg*. Nov 2014; 98(5):1730-1736. PMID 25218678
19. Date H. Update on living-donor lobar lung transplantation. *Curr Opin Organ Transplant*. Oct 2011; 16(5):453-457. PMID 21836512
20. Eberlein M, Reed RM, Chahla M, et al. Lobar lung transplantation from deceased donors: A systematic review. *World J Transplant*. Feb 24 2017; 7(1):70-80. PMID 28280698
21. Barr ML, Schenkel FA, Bowdish ME, et al. Living donor lobar lung transplantation: current status and future directions. *Transplant Proc*. Nov 2005; 37(9):3983-3986. PMID 16386604
22. Date H, Sato M, Aoyama A, et al. Living-donor lobar lung transplantation provides similar survival to cadaveric lung transplantation even for very ill patients. *Eur J Cardiothorac Surg*. Jun 2015; 47(6):967-972; discussion 972-973. PMID 25228745
23. Date H, Shiraishi T, Sugimoto S, et al. Outcome of living-donor lobar lung transplantation using a single donor. *J Thorac Cardiovasc Surg*. Sep 16 2012; 144(3):710-715. PMID 22717276
24. Slama A, Ghanim B, Klikovits T, et al. Lobar lung transplantation--is it comparable with standard lung transplantation? *Transpl Int*. Sep 2014; 27(9):909-916. PMID 24810771
25. Kilic A, Beaty CA, Merlo CA, et al. Functional status is highly predictive of outcomes after redo lung transplantation: an analysis of 390 cases in the modern era. *Ann Thorac Surg*. Nov 2013; 96(5):1804-1811. PMID 23968759
26. Kawut SM. Lung retransplantation. *Clin Chest Med*. Jun 2011; 32(2):367-377. PMID 21511096
27. Biswas Roy S, Panchanathan R, Walia R, et al. Lung retransplantation for chronic rejection: a single-center experience. *Ann Thorac Surg*. Nov 1 2018; 105(1):221-227. PMID 29100649
28. Organ Procurement and Transplantation Network (OPTN). National Data. n.d.; Available at: <<https://optn.transplant.hrsa.gov>> (accessed July 28, 2025).

29. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med*. Mar 15 2011; 183(6):788-824. PMID 21471066
30. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med*. Jul 15 2015; 192(2):e3-19. PMID 26177183
31. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and < Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. May 01 2022; 205(9):e18-e47. PMID 35486072
32. Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. *Eur Respir J*. Dec 2014; 44(6):1479-1503. PMID 25359357
33. Hayes D, Jennerich AL, Coleman RD, et al. Interventional Strategies for Children with Progressive Pulmonary Hypertension Despite Optimal Therapy: An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. Feb 2025; 211(2):157-173. PMID 39531626
34. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. Nov 2021; 40(11):1349-1379. PMID 34419372
35. Centers for Medicare & Medicaid. Transplant. Updated June 9, 2025; Available at <<https://www.cms.gov>> (accessed July 28, 2025).

Centers for Medicare and Medicaid Services (CMS)

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <<https://www.cms.hhs.gov>>.

Policy History/Revision

Date	Description of Change
01/01/2026	Document updated. The following change was made to Coverage: Removed criteria related to ex-vivo lung perfusion systems as it will now be addressed on medical policy ADM1001.035. Added references 33 and 35; others updated and/or removed.
10/15/2024	Reviewed. No changes.
02/01/2024	Document updated with literature review. Coverage unchanged. Added references: 6, 39, 41, 42; others updated and some removed.

10/15/2022	Reviewed. No changes.
12/01/2021	Document updated with literature review. The following change was made to Coverage: Modified end-stage pulmonary disease example list. Added/updated the following references: 1-3, 5, 13, 19, 35-37, and 41.
12/15/2020	Reviewed. No changes.
04/01/2019	Document updated with literature review. Coverage unchanged. References 5-7, 13, 21-24, 30, 33-34 were added and some references removed.
01/01/2018	Document updated with literature review. The following change was made to Coverage: Experimental, investigational and/or unproven coverage statement added for Ex vivo lung perfusion systems.
12/01/2017	Reviewed. No changes.
09/01/2016	Document updated with literature review. Coverage unchanged.
01/15/2015	Document updated with literature review. The following changes were made to coverage: 1) A lobar lung transplant may be considered medically necessary for carefully selected patients with end-stage pulmonary disease; 2) Postinflammatory and interstitial pulmonary fibrosis was added to list of example conditions; 3) Lung or lobar lung transplantation, after a failed lung or lobar lung transplant, may be considered medically necessary in patients who meet the criteria for lung transplantation; and 4) Lung or lobar lung transplantation is considered experimental, investigational and/or unproven in all other clinical situations. The Rationale and References were substantially revised and reorganized. CPT/HCPCS codes updated.
10/01/2012	CPT/HCPCS code(s) updated
05/15/2003	Revised document
08/01/1999	Revised document
09/01/1998	Revised document
05/01/1996	Revised document
04/01/1996	Revised document
10/01/1994	Revised document
07/01/1993	Revised document
04/01/1992	Revised document
01/01/1992	Revised document
05/01/1990	New medical document